Sino Biopharmaceutical (HKG:1177) said its TQH3906 drug met the main goal of a mid-stage clinical trial, according to a Hong Kong bourse filing Monday.
The drug demonstrated "good safety and tolerability" in subjects with moderate-to-severe plaque psoriasis, a skin condition.
After 12 weeks of treatment, 90% of enrolled subjects achieved over three quarters of improvement in their condition, the firm said.
The drug also worked as well as other biologics in the market and was found to be superior to existing marketed oral drugs for psoriasis, Sino Biopharmaceutical said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments